Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...

The Nobel Prize in medicine was awarded to Victor Ambros, PhD, of the University of Massachusetts, and Gary Ruvkun, PhD, of ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

HCC accounts for 90% of all liver cancer cases ... NICE has backed the drug after rejecting it earlier this year due to an “improved commercial arrangement” with Sanofi – in other words ...

Dozens of over-the-counter acne products had very high levels of the known carcinogen benzene, even when they were taken ...

Recursion has partnered with several healthcare giants, such as Bayer (BAYZF) and Sanofi (SNY ... to royalties for its oncology programs. Additionally, Recursion is planning to merge with Exscientia ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment ... along with GlaxoSmithKline’s Nucala and Teva’s Cinqaero. These drugs inhibit interleukin (IL)-5, while Dupixent inhibits ...

Innovent Biologics (HKEX: 01801) has formed a strategic partnership with ASK Pharm (SZ: 002755) to commercialize limertinib, ...

Potential new benefit for home health care for seniors to be funded through Medicare drug price negotiations, likely ...